Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Shares and deals

<< Previous

Bullboard Posts

Next >>

Post by Doccoleon Dec 11, 2020 5:17pm

293 Views

Post# 32091082

Shares and deals

No question I am holding my shares right to the chest!

any comparables to a expected partnership out there? It's easy if they sell the drug for 2b, then we know what to expect per share. What about other deals?

I don't know a lot about partnerships so any info is appreciated! Bring 2021!

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"